IRIS PubliCatt

Patrono, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.451
EU - Europa 2.334
AS - Asia 850
SA - Sud America 40
AF - Africa 20
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.715
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.439
CN - Cina 550
DE - Germania 537
SE - Svezia 485
IT - Italia 352
UA - Ucraina 321
IE - Irlanda 188
FR - Francia 110
GB - Regno Unito 110
SG - Singapore 110
FI - Finlandia 71
RU - Federazione Russa 68
IN - India 50
TR - Turchia 28
IR - Iran 16
BE - Belgio 14
KR - Corea 14
CH - Svizzera 13
ES - Italia 13
BR - Brasile 12
CL - Cile 12
PH - Filippine 12
HK - Hong Kong 11
AU - Australia 10
NL - Olanda 10
CA - Canada 9
TH - Thailandia 9
CI - Costa d'Avorio 8
NZ - Nuova Zelanda 8
PK - Pakistan 8
CZ - Repubblica Ceca 7
PL - Polonia 7
VN - Vietnam 7
AT - Austria 6
EG - Egitto 6
ID - Indonesia 6
AR - Argentina 5
JP - Giappone 5
PE - Perù 5
RO - Romania 5
IQ - Iraq 4
DZ - Algeria 3
IL - Israele 3
MK - Macedonia 3
NO - Norvegia 3
VE - Venezuela 3
A1 - Anonimo 2
BH - Bahrain 2
CO - Colombia 2
GE - Georgia 2
KW - Kuwait 2
KZ - Kazakistan 2
LI - Liechtenstein 2
MD - Moldavia 2
MY - Malesia 2
NP - Nepal 2
PT - Portogallo 2
BD - Bangladesh 1
BG - Bulgaria 1
CM - Camerun 1
CR - Costa Rica 1
EC - Ecuador 1
GR - Grecia 1
KE - Kenya 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
MX - Messico 1
SA - Arabia Saudita 1
SD - Sudan 1
SI - Slovenia 1
SV - El Salvador 1
TJ - Tagikistan 1
TW - Taiwan 1
Totale 5.715
Salva come PNG Salva come JPEG
Città #
Chandler 408
Ashburn 231
Jacksonville 184
Dublin 174
San Mateo 156
Nanjing 133
Hangzhou 102
Wilmington 94
Beijing 90
Cattolica 87
Woodbridge 81
Ann Arbor 70
Boston 68
Lawrence 63
Menlo Park 50
Moscow 50
Houston 48
Singapore 48
Rome 47
Redwood City 45
Nanchang 41
Milan 40
Dearborn 39
Fairfield 36
Princeton 35
Seattle 29
Bremen 26
Mountain View 26
Redmond 26
Chicago 24
Shenyang 24
New York 23
Hebei 22
Boardman 21
Kunming 21
Izmir 20
Lancaster 20
Bareggio 17
Los Angeles 16
Tianjin 16
Brussels 14
University Park 12
Jiaxing 11
Leawood 11
Norwalk 11
Nürnberg 11
Augusta 10
Hounslow 10
Guangzhou 9
Abidjan 8
Detroit 8
London 8
Philadelphia 8
Pune 8
Shanghai 8
Washington 8
Edinburgh 7
Lanzhou 7
Quezon City 7
Changsha 6
Hong Kong 6
Andover 5
Busto Arsizio 5
Catania 5
Changchun 5
Jakarta 5
Marseille 5
Ankara 4
Bangkok 4
Brno 4
Chieti 4
Florence 4
Garanhuns 4
Hefei 4
Indiana 4
Jinan 4
Karlsruhe 4
Kish 4
Latham 4
Lima 4
Münster 4
Salò 4
Santiago 4
Uster 4
Vienna 4
Aberdeen 3
Auckland 3
Avon 3
Cambridge 3
Coleraine 3
Falls Church 3
Groningen 3
Henderson 3
Islamabad 3
Kouba 3
Madrid 3
Melipilla 3
Monmouth Junction 3
Munich 3
North York 3
Totale 3.086
Salva come PNG Salva come JPEG
Nome #
Antiplatelet agents for the treatment and prevention of atherothrombosis 161
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 141
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes 127
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 116
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 112
In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus 110
Aspirin Continues to Attract Research and Debate, 115 Years After Its Synthesis 106
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 103
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes 98
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 98
Nutraceuticals in diabetes and metabolic syndrome. 95
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) 89
Increased thromboxane biosynthesis in essential thrombocythemia. 85
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. 83
Drug insight: aspirin resistance- fact or fashion 82
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 82
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. 81
Platelet activation and atherothrombosis 80
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 80
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 76
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 76
Type 2 Diabetes, Obesity, and Aspirin Responsiveness* 74
Aspirin: promise and resistance in the new millennium. 73
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells 73
The future of antiplatelet therapy in cardiovascular disease 71
Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C →T polymorphism 71
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia 71
Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective 71
Antiplatelet therapy:aspirin for asymptomatic atherosclerosis? 70
Non-steroidal anti-inflammatory drugs 68
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 68
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 68
Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment 66
Aspirin 64
Platelet progenitors: the hidden drug target 63
Low-dose aspirin for the prevention of atherothrombosis 63
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy 61
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials 61
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) 60
Low-Dose Aspirin, Coxibs, and other NSAIDS: A clinical Mosaic Emerges. 60
Determinants of platelet activation in Alzheimer's disease. 60
Aspirin 59
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. 58
Eicosanoid biosynthesis and metabolism in myeloproliferative disorders 57
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials 57
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 57
Fourth universal definition of myocardial infarction (2018) 57
Determinants of the interindividual variability in response to antiplatelet drugs. 55
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective 55
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 54
Prostanoids, aspirin and related compounds 53
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 53
The role of aspirin in cancer prevention 52
Nonsteroidal antiinflammatory drugs: past, present and future 52
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety 52
The coxibs, selective inhibitors of cyclooxygenase-2 50
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. 49
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 49
Cigarette smoking knowledge and perceptions among students in four italian medical schools 48
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 48
Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. 47
Interindividual Variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of the evidence 47
Aspirin and Other COX-1 Inhibitors 47
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs 47
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 46
Diabetes: Does aspirin increase the risk of major bleeds? 45
The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis 45
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 43
The P2Y12 receptor: no active metabolite, no party 42
Aspirin, 110 years later 41
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets 40
Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? 40
Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development 40
Antiplatelet Therapy 40
The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin 39
Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial 39
Mechanisms, consequences, and prevention of coronary graft failure 38
In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease 37
Selective COX-2 inhibitors: where do we go from here? 36
Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development 34
Nonsteroidal anti-inflammatory drugs and the heart 34
Knowledge about health effects of cigarette smoking and quitting among Italian university students: the importance of teaching nicotine dependence and treatment in the medical curriculum 34
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance" 32
Measurement of Thromboxane Biosynthesis in Health and Disease 32
Aspirin at 120: Retiring, recombining, or repurposing? 32
Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer 31
Role of Clinical Pharmacology in the Development of Antiplatelet Drugs 29
Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now 29
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 26
Aspirin and Cancer 26
Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus. Role of interleukin-6 and disease duration. 25
Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation 20
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials 20
Less Thromboxane, Longer Life 20
Precision antiplatelet therapy 19
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 19
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Implications for Aspirin "Resistance" 19
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs 18
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera 16
Platelet activation in obese women: role of inflammation and oxidant stress 15
Totale 5.761
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.135
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.135
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020513 0 25 33 22 59 44 37 33 44 47 86 83
2020/2021770 71 83 9 75 104 74 73 23 87 15 124 32
2021/2022787 73 74 12 51 62 21 25 128 38 25 112 166
2022/20231.367 209 189 123 164 146 160 37 93 145 23 51 27
2023/2024797 23 235 35 81 36 53 57 30 14 34 91 108
2024/202548 34 14 0 0 0 0 0 0 0 0 0 0
Totale 5.813